Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CCR2 | P41597 | 8/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782283 | 0.83 | CCR2 (0.42) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL3782896 | 0.83 | CCR2 (0.44) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL13222974 | 0.82 | CCR2 (0.47) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL3037271 | 0.80 | CCR2 (0.45) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL3034202 | 0.80 | CCR2 (0.45) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL3029479 | 0.80 | CCR2 (0.45) | CCR2KCNH2TACR1TSHRUSP2 | |
| SCHEMBL3038616 | 0.80 | TACR1 (0.47) | SIGMAR1CCR2CCR3TACR1TSHR | |
| SCHEMBL3784983 | 0.80 | CCR2 (0.44) | DRD4CCR2KCNH2TACR1TSHR | |
| SCHEMBL3787808 | 0.79 | CCR2 (0.42) | DRD4SIGMAR1CCR2KCNH2TACR1 | |
| SCHEMBL3038231 | 0.79 | GAA (0.49) | CCR2KCNH2TSHRCYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | DRD4 2433/4885TMEM97 990/4885SIGMAR1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.